中华老年心脑血管病杂志

[1]Pokharel Y,Tang F,Jones PG,et al.Adoption of the 2013American College of Cardiology/American Heart Association cholesterol management guideline in cardiology practices nationwide[J].JAMA Cardiol,2017,2(4):361-369.DOI:10.1001/jamacardio.2016.5922.

[2]Zhang H,Plutzky J,Skentzos S,et al.Discontinuation of statins in routine care settings:a cohort study[J].Ann Intern Med,2013,158(7):526-534.DOI:10.7326/0003-4819-158-7-201304020-00004.

[3]Bruckert E,Hayem G,Dejager S,et al.Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO Study[J].Cardiovasc Drugs Ther,2005,19(6):403-414.DOI:10.1007/s10557-005-5686-z.

[4]Seidah NG,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosis-regulated convertase 1(NARC-1):liver regeneration and neuronal differentiation[J].Proc Natl Acad Sci U S A,2003,100(3):928-933.DOI:10.1073/pnas.0335507100.

[5]Cohen JC,Boerwinkle E,Mosley TH Jr,et al.Sequence variations in PCSK9,low LDL,and protection against coronary heart disease[J].N Engl J Med,2006,354(12):1264-1272.DOI:10.1056/NEJMoa054013.

[6]Lambert G,Sjouke B,Choque B,et al.The PCSK9decade[J].J Lipid Res,2012,53(12):2515-2524.DOI:10.1194/jlr.R026658.

[7]Roubtsova A,Munkonda MN,Awan Z,et al.Circulating proprotein convertase subtilisin/kexin 9(PCSK9)regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue[J].Arterioscler Thromb Vasc Biol,2011,31(4):785-791.DOI:10.1161/ATVBAHA.110.220988.

[8]Dias CS,Shaywitz AJ,Wasserman SM,et al.Effects of AMG145on low-density lipoprotein cholesterol levels:results from2randomized,double-blind,placebo-controlled,ascending-dose phase 1studies in healthy volunteers and hypercholesterolemic subjects on statins[J].J Am Coll Cardiol,2012,60(19):1888-1898.DOI:10.1016/j.jacc.2012.08.986.

[9]Sullivan D,Olsson AG,Scott R,et al.Effect of a monoclonal antibody to PCSK9on low-density lipoprotein cholesterol levels in statin-intolerant patients:the GAUSS randomized trial[J].JAMA,2012,308(23):2497-2506.DOI:10.1001/jama.2012.25790.

[10]Stroes E,Colquhoun D,Sullivan D,et al.Anti-PCSK9antibody effectively lowers cholesterol in patients with statin intolerance:the GAUSS-2randomized,placebo-controlled phase3clinical trial of evolocumab[J].J Am Coll Cardiol,2014,63(23):2541-2548.DOI:10.1016/j.jacc.2014.03.019.

[11]Nissen SE,Stroes E,Dent-Acosta RE,et al.Efficacy and tolerability of evolocumab vs ezetimibe in patients with musclerelated statin intolerance:the GAUSS-3Randomized Clinical Trial[J].JAMA,2016,315(15):1580-1590.DOI:10.1001/jama.2016.3608.

[12]Raal FJ,Honarpour N,Blom DJ,et al.Inhibition of PCSK9with evolocumab in homozygous familial hypercholesterolaemia(TESLA Part B):a randomised,double-blind,placebocontrolled trial[J].Lancet,2015,385(9965):341-350.DOI:10.1016/S0140-6736(14)61374-X.

[13]Raal F,Scott R,Somaratne R,et al.Low-density lipoprotein cholesterol-lowering effects of AMG 145,a monoclonal antibody to proprotein convertase subtilisin/kexin type 9serine protease in patients with heterozygous familial hypercholesterolemia:the reduction of LDL-C with PCSK9inhibition in heterozygous familial hypercholesterolemia disorder(RUTHERFORD)randomized trial[J].Circulation,2012,126(20):2408-2417.DOI:10.1161/CIRCULATIONAHA.112.144055.

[14]Raal FJ,Stein EA,Dufour R,et al.PCSK9inhibition with evolocumab(AMG 145)in heterozygous familial hypercholesterolaemia(RUTHERFORD-2):a randomised,double-blind,placebo-controlled trial[J].Lancet,2015,385(9965):331-340.DOI:10.1016/S0140-6736(14)61399-4.

[15]Raal FJ,Hovingh GK,Blom D,et al.Long-term treatment with evolocumab added to conventional drug therapy,with or without apheresis,in patients with homozygous familial hypercholesterolaemia:an interim subset analysis of the OpenLabel TAUSSIG Study[J].Lancet Diabetes Endocrinol,2017,5(4):280-290.DOI:10.1016/S2213-8587(17)30044-X.

[16]Sabatine MS,Giugliano RP,Keech AC,et al.Evolocumab and clinical outcomes in patients with cardiovascular disease[J].N Engl J Med,2017,376(18):1713-1722.DOI:10.1056/NEJMoa1615664.

[17]Sabatine MS,Giugliano RP,Wiviott SD,et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1500-1509.DOI:10.1056/NEJMoa1500858.

[18]Koren MJ,Sabatine MS,Giugliano RP,et al.Long-term lowdensity lipoprotein cholesterol-lowering efficacy,persistence,and safety of evolocumab in treatment of hypercholesterolemia:results up to 4years from the open-label OSLER-1Extension Study[J].JAMA Cardiol,2017,2(6):598-607.DOI:10.1001/jamacardio.2017.0747.

[19]Hirayama A,Yamashita S,Inomata H,et al.One-year efficacy and safety of evolocumab in Japanese patients-apooled analysis from the Open-Label Extension OSLER Studies[J].Circ J,2017,81(7):1029-1035.DOI:10.1253/circj.CJ-16-1016.

[20]Robinson JG,Nedergaard BS,Rogers WJ,et al.Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia:the LAPLACE-2randomized clinical trial[J].JAMA,2014,11(18):1870-1882.DOI:10.1001/jama.2014.4030.

[21]Villa G,Lothgren M,Kutikova L,et al.Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain[J].Clin Ther,2017,39(4):771-786.DOI:10.1016/j.clinthera.2017.02.011.

[22]Blom DJ,Hala T,Bolognese M,et al.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia[J].N Engl J Med,2014,370(19):1809-1819.DOI:10.1056/NEJMoa1316222.

[23]Desai NR,Giugliano RP,Zhou J,et al.AMG 145,a monoclonal antibody against PCSK9,facilitates achievement of national cholesterol education program-adult treatment panelⅢlow-density lipoprotein cholesterol goals among high-risk patients:an analysis from the LAPLACE-TIMI 57 Trial(LDL-C assessment with PCSK9monoclonal antibody inhibition combined with statin therapy-thrombolysis in myocardial infarction 57)[J].J Am Coll Cardiol,2014,63(5):430-433.DOI:10.1016/j.jacc.2013.09.048.

[24]Toth PP,Descamps O,Genest J,et al.Pooled safety analysis of evolocumab in over 6000patients from double-blind and open-label extension studies[J].Circulation,2017,135(19):1819-1831.DOI:10.1161/CIRCULATIONAHA.116.025233.

[25]Giugliano RP,Mach F,Zavitz K,et al.Design and rationale of the EBBINGHAUS Trial:aphase 3,double-blind,placebocontrolled,multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-a cognitive study of patients enrolled in the FOURIER Trial[J].Clin Cardiol,2017,40(2):59-65.DOI:10.1002/clc.22678.

[26]Mbikay M,Sirois F,Mayne J,et al.PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities[J].FEBS Lett,2010,584(4):701-706.DOI:10.1016/j.febslet.2009.12.018.

[27]Blom DJ,Koren MJ,Roth E,et al.Evaluation of the efficacy,safety and glycaemic effects of evolocumab(AMG 145)in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome[J].Diabetes Obes Metab,2017,19(1):98-107.DOI:10.1111/dom.12788.

[28]Law MR,Wald NJ,Rudnicka AR.Quantifying effect of statins on low density lipoprotein cholesterol,ischaemic heart disease,and stroke:systematic review and meta-analysis[J].BMJ,2003,326(7404):1423-1427.DOI:10.1136/bmj.326.7404.1423.

[29]Mora S,Wenger NK,Demicco DA,et al.Determinants of residual risk in secondary prevention patients treated with highversus low-dose statin therapy:the treating to new targets(TNT)study[J].Circulation,2012,125(16):1979-1987.DOI:10.1161/CIRCULATIONAHA.111.088591.

[30]Chaudhary R,Garg J,Shah N,et al.PCSK9inhibitors:a new era of lipid lowering therapy[J].World J Cardiol,2017,9(2):76-91.DOI:10.4330/wjc.v9.i2.76.

[31]Glerup S,Schulz R,Laufs U,et al.Physiological and therapeutic regulation of PCSK9activity in cardiovascular disease[J].Basic Res Cardiol,2017,112(3):32.DOI:10.1007/s00395-017-0619-0.